Merck Kgaa (MKGAF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Merck Investor and Analyst Conference call on second quarter 2025. As a reminder, all participants will be in a listen-only mode. I am now handing over to Florian Schrader, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir. Thank you very much, Heidi, and a heartfelt welcome to the Merck Q2 2025 results call. I am Florian Schreder, the Head of Investor Relations at Merck. It is my pleasure to be joined today by Belen Garrigio, our Group CEO, and Helene von Röder, our Group CFO. For the Q&A segment of this call, we will also have Jean-Charles Wirth, CEO Life Science, Denny Basohar, CEO Healthcare, and Kai Beckmann, CEO Electronics, with us. In the initial minutes of this call, we will guide you through the key slides of the presentation. Following that, we will be glad to address your questions. With that, I would like to hand it over to Belen to begin. Thank you, Florian. Welcome, everybody, to our Q2 earnings call. And before starting with the highlights of the quarter, I'm happy to remind everybody that we just announced the closing of the diversity of surface solutions last week. The closure of this transaction will allow us to sharpen our focus on high-tech application within electronics, so that is an important milestone achieved recently. And this comes just one month after we closed the acquisition of Springworks in a record time, immediately accelerating the growth of healthcare and securing the sustainability of our healthcare pillar in the mid to long term. So we are actively working on and executing our portfolio composition to enhance Merck's position as a globally diversified science and technology company with attractive growth. Returning to the quarter, I'm now on slide five...